News

“Today’s approval marks another milestone in the transformational power of gene and cell therapies to treat a wide range of diseases,” said Acting FDA Commissioner Ned Sharpless, M.D.

KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were

The study is being led by Dr. Chase Heaton, M.D., a leading oncologic head and neck surgeon at UCSF, and was developed in collaboration with Dr. Alain Algazi,

Shingrix is a non-live and recombinant subunit adjuvanted vaccine, which will be administered intramuscularly in two doses. Shingles is caused by the reactivation of the varicella zoster virus

The licensing rights of Raxone to Chiesi Group will be applicable in all countries with the exception of the US and Canada and in LHON and all other

Inheris will be responsible for launch preparation and commercialization for NKTR-181, a novel, first-in-class, investigational opioid molecule. NKTR-181 is currently under review with the U.S. Food and Drug

This revolutionary platform empowers scientists in the pharmaceutical industry to generate novel drug-like compounds by combining powerful methods for molecule generation, ADMET prediction, and high-throughput ligand-protein interaction prediction.

SORILUX is now approved for treating plaque psoriasis of the scalp and body in patients aged 12 years and older. The FDA approved SORILUX in 2010 based on

Based in Copenhagen, Nuevolution shares its advanced discovery platform and programmes with pharmaceutical and biotechnology companies to develop novel medical treatment options for the patients. Amgen’s offer represents